Free Access
Issue
Med Sci (Paris)
Volume 30, Number 4, Avril 2014
Page(s) 439 - 444
Section Microenvironnements tumoraux : conflictuels et complémentaires
DOI https://doi.org/10.1051/medsci/20143004020
Published online 05 May 2014
  1. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970 ; 13 : 1–27. [PubMed] [Google Scholar]
  2. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007 ; 450 : 903–907. [CrossRef] [PubMed] [Google Scholar]
  3. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011 ; 331 : 1565–1570. [CrossRef] [PubMed] [Google Scholar]
  4. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001 ; 410 : 1107–1111. [CrossRef] [PubMed] [Google Scholar]
  5. Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991 ; 254 : 1643–1647. [CrossRef] [PubMed] [Google Scholar]
  6. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012 ; 12 : 298–306. [CrossRef] [PubMed] [Google Scholar]
  7. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006 ; 313 : 1960–1964. [CrossRef] [PubMed] [Google Scholar]
  8. Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 2007 ; 67 : 1883–1886. [CrossRef] [PubMed] [Google Scholar]
  9. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005 ; 353 : 2654–2666. [CrossRef] [PubMed] [Google Scholar]
  10. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007 ; 117 : 1466–1476. [CrossRef] [PubMed] [Google Scholar]
  11. Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008 ; 8 : 299–308. [CrossRef] [PubMed] [Google Scholar]
  12. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010 ; 363 : 411–422. [CrossRef] [PubMed] [Google Scholar]
  13. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 ; 363 : 711–723. [CrossRef] [PubMed] [Google Scholar]
  14. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012 ; 366 : 2455–2465. [CrossRef] [PubMed] [Google Scholar]
  15. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011 ; 364 : 2517–2526. [CrossRef] [PubMed] [Google Scholar]
  16. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012 ; 366 : 2443–2454. [CrossRef] [PubMed] [Google Scholar]
  17. Bindea G, Mlecnik B, Fridman WH, et al. Natural immunity to cancer in humans. Curr Opin Immunol 2010 ; 22 : 215–222. [CrossRef] [PubMed] [Google Scholar]
  18. Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology - analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011 ; 8 : 711–719. [CrossRef] [PubMed] [Google Scholar]
  19. Nagtegaal ID, Quirke P, Schmoll HJ. Has the new TNM classification for colorectal cancer improved care ?. Nat Rev Clin Oncol 2012 ; 9 : 119–123. [CrossRef] [Google Scholar]
  20. Angell HK, Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 2013 ; 25 : 261–267. [CrossRef] [PubMed] [Google Scholar]
  21. Mlecnik B, Tosolini M, Charoentong P, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010 ; 138 : 1429–1440. [CrossRef] [PubMed] [Google Scholar]
  22. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive and mechanistic signatures. Immunity 2013 ; 39 : 11–26. [CrossRef] [PubMed] [Google Scholar]
  23. Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011 ; 29 : 610–618. [CrossRef] [PubMed] [Google Scholar]
  24. Pages F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 2009 ; 27 : 5944–5951. [CrossRef] [PubMed] [Google Scholar]
  25. Galon J, Franck P, Marincola FM, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012 ; 10 : 205. [CrossRef] [PubMed] [Google Scholar]
  26. Galon J, Pages F, Marincola FM, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012 ; 10 : 205. [CrossRef] [PubMed] [Google Scholar]
  27. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011 ; 378 : 1812–1823. [CrossRef] [PubMed] [Google Scholar]
  28. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008 ; 455 : 1069–1075. [CrossRef] [PubMed] [Google Scholar]
  29. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994 ; 330 : 1260–1266. [CrossRef] [PubMed] [Google Scholar]
  30. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006 ; 66 : 3992–3995. [CrossRef] [PubMed] [Google Scholar]
  31. Vacchelli E, Galluzzi L, Fridman WH, et al. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012 ; 1 : 179–188. [CrossRef] [PubMed] [Google Scholar]
  32. Morris M, Platell C, Iacopetta B. Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res 2008 ; 14 : 1413–1417. [CrossRef] [PubMed] [Google Scholar]
  33. Vacchelli E, Galluzzi L, Eggermont A, et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012 ; 1 : 894–907. [CrossRef] [PubMed] [Google Scholar]
  34. Vacchelli E, Martins I, Eggermont A, et al. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012 ; 1 : 1557–1576. [CrossRef] [PubMed] [Google Scholar]
  35. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011 ; 364 : 2119–2127. [CrossRef] [PubMed] [Google Scholar]
  36. Hamid O, Schmidt H, Nissan A, prospective phase II A, et al. trial exploring the association between tumor microenvironment biomarkers, clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011 ; 9 : 204. [CrossRef] [PubMed] [Google Scholar]
  37. Fridman WH, Sautès-Fridman C. Le microenvironnement tumoral : matrice nourricière, champ de bataille et cible thérapeutique des cancers. Med Sci (Paris) 2014 ; 30 : 359–365. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  38. Robert C, Mateus C. Anticorps anti-CTLA-4 : une avancée thérapeutique majeure dans le traitement du mélanome métastatique. Med Sci (Paris) 2011 ; 27 : 850–858. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  39. Garaude J. Mobiliser l’immunité innée dans le traitement des cancers. Med Sci (Paris) 2013 ; 29 : 985–990. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.